Latest News for: ckd

Edit

Kidney disease breakthrough: New drug shows tremendous promise for nearly 800 million patients with CKD

The Times of India 13 Jun 2026
For millions of people who are suffering from chronic kidney disease (CKD), diagnosis comes with a tough truth ... The search has been on for treatments that do more than manage symptoms — they needed something that goes after CKD at its root.Finerenone.
Edit

Phase III FIND‑CKD Results Show Bayer’s KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of ...

Caledonian Record 05 Jun 2026
WHIPPANY, N.J.--(BUSINESS WIRE)--Jun 5, 2026-- ....
Edit

Finerenone significantly reduced the risk of kidney disease progression and cardiovascular outcomes in broad patient populations with CKD (Bayer AG)

Public Technologies 05 Jun 2026
Finerenone significantly reduced the risk of kidney disease progression and cardiovascular outcomes in broad patient populations with CKD ... CKD is a common and potentially deadly condition that is widely underrecognized.
Edit

Phase III FIND CKD Results Show Bayer’s KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non Diabetic Chronic Kidney Disease (Bayer Corporation)

Public Technologies 05 Jun 2026
KERENDIA is currently approved by the FDA for use in adults with chronic kidney disease (CKD) associated with type 2 diabetes (T2D), as well as adults with heart failure (HF) with left ventricular ejection fraction (LVEF) ≥40%.2.
Edit

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease ...

Hastings Tribune 02 Jun 2026
WHIPPANY, N.J.--(BUSINESS WIRE)--Jun 2, 2026-- ... .
Edit

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026 (Bayer Corporation)

Public Technologies 02 Jun 2026
Initial results from the INFINITY pooled analysis which includes data from clinical studies of KERENDIA across adults with either type 2 diabetes (T2D) and chronic kidney disease (CKD) or nd-CKD ... CKD associated with T2D ... Chronic kidney disease (CKD).
Edit

ESH 2026 Presentation: Lorundrostat for Hypertension in CKD: Results From the LAUNCH-HTN Trial (Mineralys Therapeutics Inc)

Public Technologies 01 Jun 2026
). The text version of this document is not available ... Attachments Permalink. Disclaimer.
Edit

SGLT2 Inhibitors Entrenched as Foundational CKD Therapy While GLP-1 Adoption Remains Selective, According to Spherix ...

Nasdaq Globe Newswire 13 May 2026
... while one-third report no perceived benefit of GLP-1s in CKD.
Edit

SGLT2 Inhibitors Entrenched as Foundational CKD Therapy While GLP-1 Adoption Remains Selective,

Hastings Tribune 13 May 2026
Exton, PA, May 13, 2026 (GLOBE NEWSWIRE) -- ...
Edit

Reference 12 - CDC CKD factsheet 2026 (The eRulemaking Program)

Public Technologies 06 May 2026
CKD stages 1-4 using data from the August 2021-August 2023 National Health and Nutrition Examination Survey (NHANES) and the CKD Epidemiology Collaboration (CKD-EPI) equation without race.
Edit

How It Works: ‘Knock-down’ vehicle assembly

Driving 06 May 2026
Read More ....
Edit

Can kidney patients eat fruits? Doctor shares safe choices for every CKD stage

Indian Express 22 Apr 2026
From apples to mangoes, a stage-wise guide to choosing the right fruits in kidney disease .
Edit

Chronic Kidney Disease (CKD) quality improvement project 2026 to 2027 Year 2 (Welsh Government)

Public Technologies 01 Apr 2026
In appreciation of this additional time requirement, and the delay in practice visibility of the DHCW-commissioned CKD dashboards/HEIW CKD e-module, a one-year extension of the CKD QIP has been ...
Edit

Chronic Kidney Disease (CKD) Anemia Market Report 2031: Drivers, Challenges, and Competitive Landscape

Pharmiweb 26 Mar 2026
Chronic Kidney Disease (CKD) Anemia Market Overview.. The global chronic kidney disease (CKD) anemia market is projected to grow at a CAGR of approximately 6% over the next five years ... Rising CKD Prevalence Driving Market Growth.
Edit

20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction ...

Nasdaq Globe Newswire 24 Mar 2026
20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare ... .

Article Search

tools
×
×
×
×